What is the optimal first-line regimen for advanced non-small cell lung cancer patients with epidermal growth factor receptor mutation: a systematic review and network meta-analysis

What is the optimal first-line regimen for advanced non-small cell lung cancer patients with epidermal growth factor receptor mutation: a systematic review and network meta-analysis

Abstract Objectives There are currently various tyrosine kinase inhibitor (TKI)-based regimens available, and it can be challenging for clinicians to determine the most effective and safe option due to the lack of direct comparisons between these regimens. In this study, we conducted a network meta-...

Full description

Saved in:
Bibliographic Details
Main Authors: Wengang Zhang, Xinyu Zhang, Wencheng Zhao, Zhiyi Guo, Xinyue Liu, Li Ye, Zhimin Chen, Kandi Xu, Yujin Liu, Hao Wang, Lishu Zhao, Qianqian Zhang, Yujie Li, Xuyang Chen, Yayi He
Format: Article
Language:English
Published: BMC 2024-12-01
Series:BMC Pulmonary Medicine
Subjects:
Epidermal growth factor receptor
Tyrosine kinase inhibitors
Osimertinib
Network meta-analysis
Non-small cell lung cancer
Online Access:https://doi.org/10.1186/s12890-024-03438-3
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s12890-024-03438-3

Similar Items